Skip to main content

Advertisement

Table 4 Function of proteins biomarkers in relation to ovarian cancer and platelets

From: Platelet protein biomarker panel for ovarian cancer diagnosis

Protein name Associated pathologic conditions
ovarian cancer platelet disorders
ACTN1 not studied macrotrombocytopenia [37, 38]
ACTN4 ↑ in ovarian cancer [39] myelodysplastic syndrome [38, 40]
CD41/CD61 platelets contribute to ovarian cancer growth [35] deficient in Glanzmann thrombasthenia type II [41]
CRKL ↑ in ovarian cancer [42] ST - elevated myocadial infarction [43]
ERP29 not studied mediator of thrombus formation [44]
GELS ↑ in serum in ovarian cancer [45] ↑ in megakaryoblastic leukemia [46], ↑ in thrombin-activated platelets [47]
HSPA8 ↑ in ovarian cancer, a potential therapy target [48] mediator of thromboembolism [49]
MPST not studied not clarified
PHB ↑ in paclitaxel-resistant ovarian cancer [30] ↓ in platinum-resistant ovarian cancer [32] mediator of platelet aggregation [50]
SRC therapy-target for thyrosine-kinase inhibitor in ovarian cancer [51], resistance to cis-platin [33] ST - elevated myocadial infarction [43]
SERPINB6 not studied inhibitor of thrombin [25]
TLN1 ↑ in ovarian cancer [52], resistance to cis-platin [33] myelodysplastic syndrome [40]
TUBB1, TUBA4 ↑ in ovarian cancer, mediator of paclitaxel resistance [31] ↑ in thrombin-activated platelets [47], gene mutation in autosomal dominant macrothrombocytopenia [25]
WDR1 ↑ in ovarian cancer [53], resistance to cis-platin [34] mediator of TLN1-induced activation of CD41/CD61 [54]
  1. ↑ corresponds up-regulation, ↓ corresponds down-regulation